相关实验视频

Updated: Jul 14, 2026

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

Published on: May 22, 2019

基洛斯塔抑制的RhoA/NF-κB信号减轻海马炎症和中风后抑郁症

Yuling Zhang^1,2, Yichen Li², Yafang Wu²

¹School of Biological Science and Technology, Liupanshui Normal University, Liupanshui, China.

Frontiers in pharmacology

|September 19, 2025

概括

奇洛斯塔是一种中风治疗药物,通过减少海马炎症和微质激活,有效地预防小鼠中风后抑郁症 (PSD). 这种机制涉及抑制RhoA/NF-κB通路,提供神经保护和缓解抑郁行为.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
脑卒中研究脑卒中研究

背景情况:

脑卒中后抑郁症 (PSD) 影响了三分之一的幸存者,缺乏预防性治疗.
一种中风治疗药物西洛斯塔显示出PSD预防的潜力,但其机制尚不清楚.

研究的目的:

阐明基洛斯塔可以防止PSD发展的分子途径.
研究基洛斯塔的神经保护作用及其对海马体炎症和神经元亡的影响.

主要方法:

使用中脑动脉阻塞 (MCAO) 建立了缺血性中风 (IS) 的小鼠模型.
在IS小鼠中诱导PSD使用慢性不可预测的轻度压力 (CUMS) 并用cilostazol治疗.
评估行为变化和分析海马组织的神经细胞亡,微质激活和炎症标志物,使用Nissl染色,免疫光,西斑和qPCR.

主要成果:

在IS小鼠中,基洛斯塔抑制了海马微质激活和促炎性细胞因子表达.
在用西洛斯塔治疗的小鼠中观察到减弱的神经细胞亡和减轻抑郁行为.
在体外研究表明,基洛斯塔抑制微质中的RhoA/NF-κB信号通路,减少炎症性细胞因子分泌.

结论:

奇洛斯塔通过通过RhoA/NF-κB通路抑制微质激活和炎症来预防PSD.
这种神经保护作用,可能由cAMP调解,可以减少微质诱导的神经元损伤.
锡洛斯塔显示出作为PSD预防治疗剂的潜力.

关键词:

在RhoA/NF-κB信号传输中.基洛斯塔佐尔 (cilostazol) 是一种可靠的药物.海马体炎症是指海马体的炎症.微质激活的微质激活神经元的亡是神经元的亡.脑卒中后的抑郁症是什么

更多相关视频

A Preclinical Model to Assess Brain Recovery After Acute Stroke in Rats

A Preclinical Model to Assess Brain Recovery After Acute Stroke in Rats

Published on: November 6, 2019

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

相关概念视频

NF-κB-dependent Signaling Pathway

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...